Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023380 (lethargy)
 5,697 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The student population at Edinburgh University was surveyed in 1974 to collect data on women's menstrual cycles and to examine sources of individual differences in reporting symptoms associated with the cycle. 2542 non-oral contraceptive (OC) users and 756 OC users provided data. Both sets of respondents were questioned about the occurrence, both premenstrually and during menstruation, of 9 symptoms. The "physical" symptoms (stomachache, backache, nausea, fainting) were more often reported during menstruation, whereas the so-called "emotional" symptoms (lethargy, irritability, depression, tension, headache) had a greater prevalence premenstrually. When the 9 menstrual symptoms were broken down by students' fields of concentration, arts students were found to report more "emotional" symptoms than those in the sciences and professions (medicine and law). Further analysis showed that only and 1st born children were slightly less likely to report symptoms than those whose nearest sibling is 7 or more years older or younger or later born children. A similar trend was found for the reporting of illness in an earlier analysis of data from this sample. When cycle length and reqularity were analyzed together, women with long and regular cycles were found to have the lowest proportion reporting symptoms during menstruating with the exception of tension, nausea, and fainting, and women with short and irregular cycles had a correspondingly high incidence of all symptoms. In addition, women with more regular cycles were more likely to report infrequent recall of dreams than those with irregular cycles. Overall, the women who are most likely to report menstrual symptoms, especially those of an "emotional" character, are more likely to report other illnesses with emotional connotations, recall their dreams more frequently, show a preference for the arts, and tend to have been brought up with older siblings. This cluster of personality attributes defines an "expressive" personaltiy in contrast to the more "controlled" style of women at the other extreme.
 ...
PMID:Variations in menstrual cycle symptom reporting. 98 37

The criteria now used in an attempt to distinguish irritable bowel syndrome from organic gastrointestinal disease rely almost entirely on symptoms of colonic origin. 'Non-colonic' symptoms, however, arising either from elsewhere in the gut or of a more general nature, are common in irritable bowel syndrome and may have even better diagnostic potential. The prevalence of these non-colonic features was assessed in 107 patients with the irritable bowel syndrome and 295 subjects with other gut disorders. Gastrointestinal type non-colonic symptoms are useful in differentiating irritable bowel syndrome from inflammatory bowel disease but, with the exception of early satiety, are not helpful when there is gastro-oesophageal or biliary disease. More general 'non-colonic' features, such as lethargy and backache, are much commoner in irritable bowel syndrome than in all the organic gastrointestinal diseases studied and have good discriminant function. Multiple logistic regression analysis identified certain features that had a particularly significant independent risk for irritable bowel syndrome. Those were lethargy (relative risk 6.7), incomplete evacuation (RR 5.2), age under 40 (RR 2.1), backache (RR 2.0), early satiety (RR 1.8), and frequency of micturition (RR 1.8). These relative risks can be multiplied together to give an overall risk when more than one of these features is present in a patient. Until a diagnostic test is available more confident diagnosis of irritable bowel syndrome can be achieved by identifying symptoms that have good discriminant function. The results of this study indicate that the non-colonic features of irritable bowel syndrome may be especially valuable in this respect.
 ...
PMID:More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology. 156 69

The diagnosis of adrenal haemorrhage complicating heparin therapy is often delayed, despite computed tomography (CT). Moreover, its pathogenesis is not clear. Adrenal haemorrhages are often seen in cases where there is no unduly excessive anticoagulation, and can be accompanied by a paradoxical thrombosis of the central adrenal vein. Symptoms usually occur within the first 8 to 12 days after starting heparin. The difficulty in establishing the diagnosis stems from the fact that symptoms are rather nonspecific: abdominal pain and backache, nausea, vomiting, lethargy, weakness, hypotension, hyperpyrexia. To confirm the diagnosis, both hormonal proof of adrenal failure and anatomic evidence of haemorrhage must be found. Early CT scans may show the haemorrhage. Several possible causes have been put forward to account for these adrenal haemorrhages. The degree of anticoagulation did not seem to be a prerequisite, 30 to 50% of patients showing no evidence of other bleeding or coagulation tests outside the therapeutic range. Capillary fragility of old age might be a factor. Stress would seem to be an important factor predisposing to adrenal haemorrhage. Many authors consider the paradoxical central vein thrombosis as a result of the haemorrhage rather than its cause, whereas other conclude the opposite. Unfortunately, to date coagulation studies are often incomplete; platelet counts were missing in most reports published before 1985. Since that date, a heparin induced thrombosis-thrombocytopaenia syndrome (HITTS), in which thrombosis may occur in any vascular bed, has been recognized with increasing frequency. Nine cases of adrenal haemorrhage associated with HITTS have been reported. It seems highly likely that a proportion of cases of heparin-related adrenal destruction are due to HITTS.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Hematoma of the adrenal glands and heparin]. 269 74

Eighteen patients with solid tumours were treated with human recombinant interferon-gamma at escalating dose levels starting at 1 X 10(6) units/m2 per infusion and rising through 3 X 10(6), 6 X 10(6), 9 X 10(6) and 22 X 10(6) to a maximum of 110 X 10(6) units/m2 per infusion. The IV infusions were given three times a week over a 4-week period. Side effects were seen in all patients, but were mild except at the highest dose. Acute dose-related effects included pyrexia, tiredness, thirst, chills and rigors. Chronic dose-related effects included anorexia, lethargy, weakness, disorientation, a trace of proteinuria and minimal rises in liver enzymes. In addition, effects were observed which were not related to dose. These included headache, nausea and vomiting, backache, myalgia, flatulence and a mild, transient reduction in neutrophils and erythrocytes. At the highest dose level dose-limiting toxicity was observed, consisting in severe tiredness and anorexia, hypotension, disorientation and changes on the electrocardiograph. Overall, toxicity was similar to that seen with preparations of interferon-alpha, except that no tolerance to the effects of interferon-gamma was noted. We observed less hepatic and haematological toxicity, but also recorded flatulence, handcramps and electrocardiograph changes, which have not been reported with interferon-alpha. When given according to this regimen, doses of 22 X 10(6) units/m2 per infusion of recombinant interferon-gamma were generally well tolerated by the patients.
 ...
PMID:A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer. 309 8

Interferon was administered intravenously on 3 consecutive days each week for 3 consecutive weeks in doses escalated each week from 10 to 20 to 30 megaunits (MU)/m2/day. Nine adult patients were treated, each of whom had undergone subtotal resection of a supratentorial anaplastic glioma within 3 weeks of beginning interferon treatment. Patients ranged in age from 34 to 71 years, and Karnofsky functional scores were 70 or greater. Evaluations included neurological examination, Karnofsky functional rating, computerized tomography brain scanning, and panels of hematologic, hepatic, renal, and coagulation testing. No dose-limiting or prohibitive toxicities were encountered, and each patient received nine interferon doses as scheduled. There were no symptoms of neurologic toxicity other than transient lethargy. Chills and fever occurred in all patients, while headache, lethargy, and back pain were experienced by half. These symptoms were most pronounced with the initial dose of each week and did not intensify with dose escalation. The most frequent side effect of interferon treatment was fever, usually peaking near the end of the initial 4-h infusion; it became less severe during the second and third weeks. Leukopenia and granulocytopenia were mild. Serum hepatic enzyme levels rose slightly during the course of interferon treatment and returned to normal after treatment was completed. Serum interferon levels reached a maximum concentration of 2,285 U/ml at the end of infusion and were proportional to the dosage. Interferon was not detectable in lumbar cerebrospinal fluid, but fluid from the tumor bed of one patient contained 120 U/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Immunobiology of primary intracranial tumors: IX. Phase I study of human lymphoblastoid interferon. 670 97

A prospective study of the emotional reaction to interval sterilization was conducted by means of interviews 1 week prior to sterilization and 7 months postoperative with 155 Buddhist Thai women aged 35 years or under, living in Bangkok, and undergoing interval laparoscopic sterilizations for socioeconomic indications. The mean age of subjects was 27.8 years, with a range of 19-35, mean duration of marriage was 8.0 years, and mean number of children was 2.8. 56.1% of the women were housewives, 77.0% had a low educational level, and 100% were of lower socioeconomic status. 65 subjects reported psychophysiologic and emotional symptoms prior to operation, 51 continued to complain of the symptoms 6 months later, and 10 women developed new symptoms postoperatively. In the preoperative interviews, 26 women complained of irritability, 25 of headache and backache, 10 of weakness and lethargy, 11 of giddiness or fainting, 5 each of palpitation and breathing difficulty, 8 of insomnia, 4 each of anorexia and gastrointestinal upset, and 3 of other conditions. Of the 10 women developing symptoms postoperatively, 6 complained of irritability, 5 of headache, 3 of insomnia, and 1 each of weakness and lethargy, giddiness or fainting, and anorexia. Irritability and headache, which accounted for most of the symptoms, were mostly mild and few required medication. Further psychiatric investigation into personal backgrounds of subjects with psychophysiologic or emotional symptoms revealed that practically all had concurrent problems with their marriages, children, finances, or relatives, with marital problems the most frequent. 35% of subjects reported postoperative menstrual disturbances, but 72% of the sample had been on oral contraceptives or IUDs, which can influence menstrual patterns. 8 and 10 women respectively reported increased sexual drive and sexual satisfaction, 6 and 3 reported decreased drive and satisfaction, and 141 and 142 reported no change in desire or satisfaction. 5 reported postoperative dyspareunia. 145 husbands and 152 wives stated they were satisfied with the operation.
 ...
PMID:Emotional reaction to female sterilization: a prospective study. 710 4

A case history is reported of a 29-year old patient who presented with a chronic illness characterized by lethargy, back pain, fever, and anemia. Evaluation disclosed the presence of a large pelvic mass which was confirmed as a tubo-ovarian abscess at surgery. Histological evaluation demonstrated involvement by Actinomyces species. The patient's illness is discussed as a complication of chronic IUD usage with reference to specific management for this emerging problem. Data from the National Fertility Study conducted in 1973 revealed that nearly 2 million married women in the US, ages 15-44, were using IUDs. Scott noted the serious potentially fatal complications associated with IUD use, including pelvic inflammatory disease (PID), uterine perforation, ectopic pregnancy, and spontaneous or septic abortion. The relative risk of PID among IUD users has been reported to be increased 2-12 fold over controls. The risk of infection appears to increase as the period of IUD use lengthens, but the risk associated with the use of copper IUDs may be slightly less than with plastic IUDs. Actinomycosis has traditionally been described in 3 anatomical regions, the cervicofacial, thoracic, and abdominal areas, but pelvic and genital disease has been recognized with increasing frequency over the past decade. The common denominator associated with the latter syndrome appears to be the concurrent presence of an IUD. The Actinomyces are gram positive, nonacid fast, anaerobic, obligate parasites which are classified somewhere between the true bacteria and the complete fungi. Actinomyces species are not generally considered part of the normal vaginal flora but rather are associated with the presence of a foreign body, most often an IUD. It is thought that the IUD causes the initial tissue injury which permits subsequent colonization by these organisms. It is not known whether orogenital contact is a means of transmission of Actinomyces to the lower genital tract of sexual partners. One might estimate that the overall rate of cytological detection of A. israelii in cervical smears of IUD users at about 10%. This incidence increases sharply in patients being evaluated for symptomatic pelvic infection. Conversely, in women with IUDs in place and Actinomyces demonstrable in cervical smears, PID is up to 4 times as common as in those who have negative smears. Antibiotic treatment should probably be dictated by the clinical setting. As a general guide, the threshold for treatment should be low, since the therapy is relatively benign and the extent to which colonization and tissue invasion may have occurred is unknown.
 ...
PMID:Pelvic actinomycosis and usage of intrauterine contraceptive devices. 718 22

We reported the results of a randomized cross-over study comparing SH D 461 M (Climen) and Prempak-C in 38 postmenopausal women who were established users of hormone replacement therapy (HRT). Climen contains 11 tablets of 2 mg estradiol valerate (EV), and 10 tablets with 2 mg EV plus 1 mg of cyproterone acetate. Prempak-C, on the other hand, is a regime consisting of 28 tablets of 0.625 mg conjugated equine estrogens (CEE); the last 12 tablets are taken together with 0.15 mg of norgestrel (NG) tablets. Patients in Sequence I started with Climen for 6 months and then crossed-over to Prempak-C, for the next 6 months; patients in Sequence II, followed the reverse order. Following Climen treatment, significantly higher levels (P < 0.05, t-test) of sex hormone binding globulin (SHBG) and estradiol, when compared to Prempak-C treated subjects, were noted. No significant differences in follicle stimulating hormone (FSH), corticosteroid binding globulin (CBG), renin, angiotensinogen, angiotensin-I and aldosterone levels between the two treatment regimes were noted. While both regimes were effective in reducing menopausal symptoms, none of the regimes could eliminate all symptoms completely. Treatment with Climen appeared to result in less frequent occurrences of some symptoms. During periods of no estrogen (only true for Climen) as well as periods of maximum progestagen and estrogen (P and E), subjects on Climen had significantly lower incidence of some of the symptoms (backache, lack of concentration, lethargy and swelling) when compared to those on Prempak-C.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Endocrine effects in Asian postmenopausal women treated with SH D 461 M and Prempak-C. 771 69

We reported the results of a randomized cross-over study comparing SH D 461 M (Climen) and Prempak-C in 38 postmenopausal women who were established users of hormone replacement therapy (HRT). Climen contains 11 tablets of 2 mg estradiol valerate (EV), and 10 tablets with 2 mg EV plus 1 mg of cyproterone acetate. Prempak-C, on the other hand, is a regimen consisting of 28 tablets of 0.625 mg conjugated equine estrogens (CEE); the last 12 tablets are taken together with 0.15 mg of norgestrel (NG) tablets. Patients in Sequence I started with Climen for 6 months and then crossed-over to Prempak-C, for the next 6 months. Patients in Sequence II followed the reverse order. Following Climen treatment, significantly higher levels (P < 0.05, t-test) of sex hormone binding globulin (SHBG) and estradiol, when compared to Prempak-C treated subjects, were noted. No significant differences in follicle stimulating hormone (FSH), corticosteroid binding globulin (CBG), renin angiotensinogen, angiotensin-I and aldosterone levels between the two treatment regimens were noted. While both regimens were effective in reducing menopausal symptoms, none of the regimens could eliminate all symptoms completely. Treatment with Climen appeared to result in less frequent occurrences of some symptoms. During periods of no estrogen (only true for Climen) as well as periods of maximum P and E, subjects on Climen had significantly lower incidence of some of the symptoms (backache, lack of concentration, lethargy and swelling) when compared to those on Prempak-C.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Endocrine effects in Asian postmenopausal women, treated with SH D 461 M and Prempak-C. 773 78

A 6-year-old, intact, female miniature Doberman pinscher was evaluated for lethargy, intermittent back pain, and unstable gait. Physical and neurological findings included bradycardia, hypothermia, hyperesthesia, progressive and ascending ataxia, and proprioceptive deficits in all limbs. Laboratory findings and magnetic resonance imaging were consistent with disseminated granulomatous meningoencephalomyelitis, confirmed later by microscopy.
 ...
PMID:Disseminated granulomatous meningoencephalomyelitis in a dog. 1180 71


1 2 3 Next >>